Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥381.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)141.59K
Market Cap
¥6.63B
Enterprise Value¥10.92B
Total Cash (Recent Filing)¥3.70B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.71
Shares Outstanding16,868,100
10 Day Avg. Volume88,320
30 Day Avg. Volume141,586
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)3.59
Price to Sales (P/S)29.38
P/FCF Ratio-26.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.9
Revenue Forecast (FY)¥1.05B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth of roughly 81% indicates improving commercial traction and expanding adoption of the company’s services. If sustained, stronger scale can provide a broader base for operating leverage, support reinvestment, and improve the long-term path toward covering the existing cost structure.
Very High Gross MarginsGross margins near 96–98% indicate that the company’s product and service mix generates substantial value after direct costs. This provides attractive potential operating leverage as revenue grows, although the benefit depends on management controlling overhead and converting gross profit into sustainable earnings.
Debt-Free Balance SheetZero debt materially reduces solvency and refinancing risk while preserving flexibility during continued investment and losses. A sizable equity base provides resilience and allows the company to fund operations without interest obligations, giving management more time to improve profitability and protect financial stability.
Bears Say
Large Operating And Net LossesDespite rapid revenue growth and high gross margins, the company remains deeply unprofitable, showing that its current cost base is too large for its revenue scale. Persistent operating and net losses could delay self-sustaining growth and require continued reliance on its capital base.
Persistent Cash BurnNegative operating and free cash flow across three consecutive years shows that reported business activity is not yet translating into internally generated funding. Continued cash burn can reduce strategic flexibility over the next several quarters and make progress toward profitability more financially demanding.
Declining Equity And Negative ReturnsAlthough capitalization remains strong, falling equity indicates that accumulated losses are consuming part of the company’s financial buffer. Negative returns on equity also show that shareholder capital is not currently producing earnings, increasing the importance of reversing losses before reserves weaken further.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥381.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥6.63B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 22 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on Aug 07, 2026. The company reported -¥2.97 earnings per share for the quarter.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥2.97 in its last earnings report. Following the earnings report the stock price went up 0.999%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.